Skip to main content

Trump tax bill estimated to cut Medicaid spend by $1trn passes US Senate

Submitted by admin on
snippet

US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance broke a 50-50 deadlock in the US Senate.

Source
Clinical Trials Arena

Is DTC pharma advertising coming to an end?

Submitted by admin on
snippet

A ban on pharma’s TV ads may finally be on the way.

Sens. Bernie Sanders, I-Vt., and Angus King, I-Maine, introduced the End Prescription Drug Ads Now Act last week that would end pharma’s ability to advertise directly to consumers.

If enacted, the bill would fulfill a goal of HHS Secretary Robert F. Kennedy Jr., who targeted TV advertisements when he was running for president and maintained that position after joining the Trump administration.

Source
Pharma Voice

Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others

Submitted by admin on
snippet

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a legislative loophole that drugmakers are allegedly lobbying to retain.

Source
Fierce Pharma

Pharma’s wins and losses in the budget bill

Submitted by admin on
snippet

Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.

Source
Pharma Voice

Drug Patent Reform’s Been Postponed Repeatedly, Is The 119th Congress Ready To Act?

Submitted by admin on
snippet

What’s noteworthy is that in this Congress the Senate Judiciary Committee has voted to advance their drug patent reform plans, re-introduced as two separate bills.

Source
Forbes
News Tags

PBMs have evaded lawmakers’ reform attempts so far. Could 2025 turn the tide?

Submitted by admin on
snippet

According to critics, PBMs drive up drug costs through an opaque rebate system, and their joint ownership structure with pharmacies and health insurers creates an unfair and anticompetitive business model. Just three companies — CVS’s Caremark, Cigna’s Express Scripts and UnitedHealthcare’s OptumRx — control the vast majority of the PBM market. And their concentrated and complex operations have been catching heat amid calls for drug pricing reform.

Source
Pharma Voice